On July 2, 2024, PW Medtech Group Limited (PW Medtech) announced that it will spin off its subsidiary, Sichuan Rekind Medtec, Inc. (Sichuan Rekind Medtec), by way of a separate quotation on the National Equities Exchange and Quotations System (NEEQS Quotation) and a subsequent listing on the Beijing Stock Exchange, subject to the then-market conditions and its strategic development needs (together with the NEEQS Quotation, the “Proposed Spin-Off”). PW Medtech has obtained approval from The Stock Exchange of Hong Kong Limited, confirming that it may proceed with the Proposed Spin-Off under Practice Note 15 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. On June 26, 2024, Sichuan Rekind Medtec submitted an application for the NEEQS Quotation. Wilson Sonsini Goodrich & Rosati acted as the Hong Kong counsel to PW Medtech in connection with the Proposed Spin-Off.

PW Medtech is a leading medical device company focused on fast-growing and high-margin segments of China’s medical device industry. It has leading market positions in its current business segments of infusion sets, blood purification products, and regenerative medical biomaterials, with strong research and development capabilities and well-established distribution networks.

Sichuan Rekind Medtec is principally engaged in research and development, manufacture, and sales of blood purification medical devices, as well as blood purification medical services for patients with kidney failure and multiple organ failure. 

The Wilson Sonsini team that advised PW Medtech on the Proposed Spin-Off includes:

Weiheng Chen
Can Yin
Haoqian Chen
Kelly Cheng